Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
12 déc. 2022 10h00 HE
|
Kymera Therapeutics, Inc.
Activity of STAT3 degrader in preclinical model of cutaneous T-cell lymphoma (CTCL) validates selective STAT3 degradation as a potential therapeutic strategy for STAT3-driven T cell malignancies ...
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
11 déc. 2022 10h00 HE
|
Kymera Therapeutics, Inc.
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL-2 inhibitor venetoclax in model of...
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
01 déc. 2022 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
03 nov. 2022 07h05 HE
|
Kymera Therapeutics, Inc.
Completed patient cohort portion (Part C) of the IRAK4 degrader KT-474 Phase 1 trial Patient data from KT-474 and clinical oncology pipeline to be presented in December, 2022 Raised $150...
Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors
03 nov. 2022 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
20 oct. 2022 07h30 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
13 oct. 2022 16h15 HE
|
Kymera Therapeutics, Inc.
Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and KT-333 continuing in Phase 1 dose escalation KT-253 has completed IND enabling studies WATERTOWN, Mass., Oct. ...
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma
15 sept. 2022 07h30 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...
Kymera Therapeutics to Participate in Upcoming September Conferences
29 août 2022 07h30 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Announces $150 Million Private Placement Equity Financing
19 août 2022 07h30 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...